Equities

Nippon Shinyaku Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Nippon Shinyaku Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)5,000.00
  • Today's Change-4.00 / -0.08%
  • Shares traded104.20k
  • 1 Year change+26.20%
  • Beta0.1008
Data delayed at least 15 minutes, as of Feb 13 2026 01:48 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nippon Shinyaku Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals and functional foods. The Company has two business segments. The Pharmaceutical Business segment conducts research and development in three focus areas: hematology, intractable and rare diseases (pulmonary arterial hypertension, muscular dystrophy, etc.), and urological and gynecological diseases. The Functional Food Business segment conducts research and development mainly in three categories: health food ingredients, quality-stabilizing preservatives, and protein preparations. Other businesses include business support, non-life insurance agency and life insurance solicitation, real estate rental, and educational support services.

  • Revenue in JPY (TTM)166.05bn
  • Net income in JPY29.85bn
  • Incorporated1919
  • Employees2.24k
  • Location
    Nippon Shinyaku Co Ltd14, Nishinosho Monguchi-cho,Kisshoin, Minami-kuKYOTO-SHI 601-8550JapanJPN
  • Phone+81 753211111
  • Fax+81 753210678
  • Websitehttps://www.nippon-shinyaku.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nxera Pharma Co Ltd28.70bn-6.14bn80.36bn374.00--1.22--2.80-68.13-68.13318.44725.520.19361.474.5776,737,970.00-4.14-1.71-4.63-1.8571.1784.07-21.41-10.932.55-11.730.4902--125.8724.2832.74--40.57--
JCR Pharmaceuticals Co Ltd37.55bn-2.44bn88.32bn987.00--1.79189.932.35-19.98-19.98307.86379.760.34320.45342.5038,039,510.00-2.215.86-3.779.3370.4573.83-6.4513.600.668--0.529545.13-22.865.94-186.42--15.3720.11
Kyorin Pharmaceutical Co Ltd133.26bn10.77bn99.81bn2.00k8.880.68886.490.749187.40187.402,319.592,417.370.69271.082.9366,695,200.005.603.347.034.1645.3245.898.085.112.05--0.174657.348.833.4170.738.1214.36-7.06
Katakura Industries Co Ltd40.98bn5.84bn109.34bn941.0017.031.0912.432.67182.30182.301,278.512,853.060.29262.156.4243,545,160.004.272.605.203.5736.1637.9814.599.442.63--0.080723.42-1.37-2.1915.7315.27-7.2233.03
Zeria Pharmaceutical Co Ltd86.61bn7.26bn112.72bn1.75k13.381.017.751.30164.79164.791,964.972,178.210.53661.273.2149,607,640.004.494.676.997.4772.7672.178.379.020.973911.410.298428.7515.307.6428.5227.7116.516.69
Mochida Pharmaceutical Co Ltd111.92bn6.42bn136.28bn1.51k20.670.96614.521.22181.16181.163,156.953,876.770.64271.673.0274,214,190.003.694.504.475.4448.4352.495.746.872.85--0.067843.012.210.651625.034.341.980.00
Kaken Pharmaceutical Co Ltd75.66bn-3.83bn186.05bn1.13k--1.09--2.46-97.11-97.111,980.563,850.390.40911.862.8067,195,380.00-2.075.99-2.426.8753.0956.17-5.0612.913.21--0.025759.5830.521.0573.77-6.3614.810.00
Towa Pharmaceutical Co Ltd266.67bn20.65bn193.44bn4.79k8.951.034.600.7254419.38419.385,417.063,653.680.57761.514.1255,694,650.004.473.895.455.0736.3837.817.746.611.5144.310.567821.5213.8918.6517.395.5346.239.73
Kissei Pharmaceutical Co Ltd95.29bn14.14bn216.89bn1.78k13.810.892711.482.28337.47337.472,274.295,220.290.37481.852.8353,596,180.005.624.266.194.6048.2148.5914.9914.303.42--0.005832.4116.876.917.1833.5431.0413.97
Sawai Group Holdings Co Ltd200.00bn309.00m277.17bn3.31k3,773.531.5717.411.390.636-11.401,703.921,531.410.55591.244.0960,422,060.000.0862-0.23270.1143-0.318729.3932.950.155-0.4750.8120.74350.3737191.656.880.7009-87.38-35.388.654.11
Tsumura & Co189.50bn29.01bn316.94bn4.27k10.671.017.431.67387.15387.152,524.844,095.990.3740.71062.4144,357,680.006.015.538.066.8547.6049.3916.0614.501.45--0.285631.6520.058.0094.1018.6923.0716.27
Nippon Shinyaku Co Ltd166.05bn29.85bn362.36bn2.24k11.641.2210.012.18443.17443.172,465.264,211.800.54211.173.1974,028,980.009.7510.8910.8112.7467.2963.9317.9817.674.04--0.008930.588.086.5625.9414.0680.487.59
Hisamitsu Pharmaceutical Co Inc159.27bn19.99bn489.32bn2.80k23.501.7017.783.07276.99276.992,208.133,837.320.47042.643.4256,901,390.006.044.347.254.9959.0557.8312.8410.323.28--0.008650.2910.092.0455.763.0829.890.7127
Data as of Feb 13 2026. Currency figures normalised to Nippon Shinyaku Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

18.08%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 15 Dec 20254.12m5.86%
The Vanguard Group, Inc.as of 07 Jan 20262.00m2.85%
Arcus Investment Ltd.as of 30 Sep 20241.11m1.57%
Norges Bank Investment Managementas of 30 Jun 20251.07m1.53%
Dimensional Fund Advisors LPas of 08 Jan 2026825.66k1.18%
Amova Asset Management Co., Ltd.as of 09 Jan 2026802.60k1.14%
Daiwa Asset Management Co. Ltd.as of 30 Dec 2025775.00k1.10%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 08 Jan 2026761.80k1.08%
BlackRock Fund Advisorsas of 08 Jan 2026730.20k1.04%
Asset Management One Co., Ltd.as of 08 Jan 2026510.80k0.73%
More ▼
Data from 30 Sep 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.